Alkeemia S.p.A.

Alkeemia S. p. A. is a European manufacturer specializing in hydrofluoric acid and its derivatives, serving various industrial sectors that require high-purity chemicals for applications such as energy, electronics, and pharmaceuticals.

Founded in 2018, Alkeemia S. p. A. operates from its headquarters in Milan, Italy, and specializes in the production of hydrofluoric acid and derivatives.

The company was acquired by Blantyre Capital in October 2021 as part of Fluorsid S. p. a. 's strategic focus on its core operations in fluorochemicals for the aluminum industry.

The company's CEO is Herbert Zweck, with Lorenzo Di Donato also holding a position of leadership. Alkeemia is a leading European manufacturer specializing in hydrofluoric acid and its derivatives, primarily serving sectors that require high-purity chemicals for various industrial applications. The company’s core product offerings include hydrofluoric acid, essential for the production of fluoropolymers and pharmaceutical intermediates, along with a range of fluorinated products aimed at the energy, electronics, and automotive industries. These products are crucial for applications such as battery manufacturing, semiconductor production, and chemical synthesis.

Alkeemia operates facilities in Porto Marghera (Venice) and Frankfurt, distributing its products across international markets, including Germany, France, and other European Union countries. In 2022, Alkeemia generated revenue of USD 66. 79 mn, with an EBITDA of USD 346,920. The company engages in direct sales of its chemical products to a diverse range of clients in the automotive, electronics, and pharmaceutical sectors, providing tailored solutions that include long-term supply agreements to ensure pricing and availability stability.

Alkeemia plans to introduce new products targeting emerging markets, with launches scheduled for the upcoming year. The company is particularly focused on expanding its presence in additional European Union countries, with specific strategies to enter markets in Eastern Europe by 2024. The funding from the acquisition by Blantyre Capital will support these initiatives, enhancing research and development capabilities and facilitating entry into these new markets.